A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer

NCT07455019 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy

Sponsor

The First Affiliated Hospital with Nanjing Medical University